Cargando…
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
BACKGROUND & AIMS: There is limited evidence on the efficacy and safety of nucleos(t) ide analogues (NAs) in the treatment of HBV-ACLF. Our objective was to evaluate the outcomes among TAF, TDF and ETV, three first-line antivirals against chronic hepatitis B, in patients with HBV-ACLF. METHODS:...
Autores principales: | Li, Juan, Hu, Chunhua, Chen, Yi, Zhang, Rou, Fu, Shan, Zhou, Mimi, Gao, Zhijie, Fu, Mengjun, Yan, Taotao, Yang, Yuan, Li, Jianzhou, Liu, Jinfeng, Chen, Tianyan, Zhao, Yingren, He, Yingli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201741/ https://www.ncbi.nlm.nih.gov/pubmed/34126939 http://dx.doi.org/10.1186/s12879-021-06237-x |
Ejemplares similares
-
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020) -
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
por: Liu, Zekun, et al.
Publicado: (2023) -
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016) -
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021) -
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)